Institute for Developmental Cancer Therapeutics Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2020
NCT04257448
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Institute for Developmental Cancer Therapeutics

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 6